Company: PTPI
Filing Date: 2025-02-10
Form Type: S-1/A
Source: 0001410578-25-000108
Chunk: 192

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-10
Form: S-1/A
Chunk 192
---
astal”). Represents (i) 1,698,282 shares of common stock issuable upon exercise of certain warrants that were exercisable as of February 6, 2025 or will be exercisable within 60 days thereafter (with certain warrants subject to a 4.99% beneficial ownership blocker), and (ii) 136.19 shares of Series A Preferred Stock, convertible into up to approximately 60,528 shares of common stock within 60 days of February 6, 2025 (subject to a 4.99% beneficial ownership blocker). |

Mr. Kopin and Mr. Asher are each managers of Intracoastal and have shared voting control and investment discretion over the securities reported herein that are held by Intracoastal. As a result, each of Mr. Kopin and Mr. Asher may be deemed to have beneficial ownership (as determined under Section 13(d) of the Exchange Act of the securities reported herein that are held by Intracoastal Capital LLC. The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483 and the principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

| (5) | Based on certain information made available to the Company. Represents (i) 666,667 shares of common stock issuable upon exercise of certain warrants that were exercisable as of February 6, 2025 or will be exercisable within 60 days thereafter (subject to a 4.99% beneficial ownership blocker), and (ii) 36.9 shares of Series A Preferred Stock, convertible into up to approximately 16,400 shares of common stock within 60 days of February 6, 2025 (subject to a 4.99% beneficial ownership blocker). |

Messrs. Arie Rabinowitz and Joe Hammer have voting and investment control over the securities held by Five Narrow Lane LP. Five Narrow Lane LP’S address is 510 Madison Avenue, Suite 1400, New York, NY 10022.

| (6) | Based on certain information made available to the Company. Represents (i) 622,222 shares of common stock issuable upon exercise of certain warrants that were exercisable as of February 6, 2025 or will be exercisable within 60 days thereafter (subject |

112

| to a 4.99% beneficial ownership